Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

Trial Profile

A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sodium oxybate (Primary)
  • Indications Hypersomnia
  • Focus Registrational; Therapeutic Use
  • Sponsors Jazz Pharmaceuticals plc
  • Most Recent Events

    • 29 Nov 2018 According to a Jazz Pharmaceuticals plc media release, first patient has been enrolled in the trial.
    • 29 Nov 2018 Status changed from not yet recruiting to recruiting, according to a Jazz Pharmaceuticals plc media release.
    • 18 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top